在GlaxoSmithKline的MATINEE试验中,Nucala在104周的研究中减少了COPD恶化. GlaxoSmithKline's MATINEE trial shows Nucala reduces COPD exacerbations in 104-week study.

GlaxoSmithKline(GSK)宣布了第三阶段MATINEE对Nucala(mepolizumab)慢性阻塞性肺病(COPD)试验的积极成果。 GlaxoSmithKline (GSK) announced positive results from its phase III MATINEE trial of Nucala (mepolizumab) for chronic obstructive pulmonary disease (COPD). 与安慰剂相比,在接受Nucala治疗的患者中,与维持治疗同时接受的患者中,在104周的时间内,中度至严重恶化显著减少. The trial showed a significant reduction in moderate to severe exacerbations in patients receiving Nucala alongside maintenance therapy compared to a placebo over 104 weeks. Nucala,以前被批准治疗重度哮喘,目标为Interleukin-5,以防治炎症。 Nucala, previously approved for severe asthma, targets interleukin-5 to combat inflammation. 今后的科学会议将分享进一步的分析和结果。 Further analysis and results will be shared at future scientific meetings.